Physician profile
Terence Isakov
NPI 1497729222
$10,160.98
in general payments reported to CMS, 2019-2025
59 companies · $976 in 2025
The $976 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,522 · 2020: $880 · 2021: $1,902 · 2022: $1,778 · 2023: $1,435 · 2024: $1,668 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,078.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,187.55 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $880.83 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $673.62 | 2019-2025 | |
| Novo Nordisk INC | $582.20 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $532.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $377.79 | 2022-2025 | |
| Astellas Pharma US INC | $346.97 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.79 | 2020-2025 | Ofev, Jardiance |
| Merck Sharp & Dohme LLC | $280.66 | 2020-2025 | Gardasil 9, Capvaxive, M-M-R II |
| E.R. Squibb & Sons, L.L.C. | $273.87 | 2019-2025 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $266.14 | 2019-2023 | Airduo Digihaler |
| Abbott Laboratories | $255.50 | 2021-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $240.92 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $214.18 | 2019-2021 | |
| Amgen INC. | $198.21 | 2019-2025 | Repatha, Otezla, Prolia |
Show all 56 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terence Isakov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.